Here's Why Epizyme Lost 27.6% in March

Shares of Epizyme (NASDAQ: EPZM) dropped more than 27% last month, according to data from S&P Global Market Intelligence. The tumble marked an abrupt end to a rally that extended back to October 2019. Shares nearly doubled from October to the beginning of March as investors cheered multiple developments for the development-stage pharmaceutical company.

While most of the progress remains intact, the coronavirus pandemic threatens to pause or delay recent commercialization efforts, including an important regulatory deadline. That promises to make the pharma stock volatile until more information is known.

Image source: Getty Images.

Source Fool.com